Free biotech catalyst calendar
Each date comes with the SEC sentence it came from. Open a line to see the sentence and how its wording has changed.Each date comes with its SEC sentence.
250 programs as of
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
These records could not be loaded. Open a numbered page to read the original quotations and SEC links.
No program matches these filters. Ask for a company on the Watch page.
About this calendar
FDA dates and trial readouts as each company stated them, with SEC original links. 250 programs as of . Free, with no sign-in. No forecasts, prices or signals.
Add to Google Calendar Apple Calendar The subscription follows the filters chosen here. No sign-up; ORION stores nothing about subscribers.
How this calendar is made
- Entries are grouped by their retained period length: a date (with its count of days), a month (counted to its last day), then a quarter, half or year with no count. Period headings describe the window end; each row retains the company's exact wording. A date is the target action date the company stated.
- Company size is the public float (market value of shares held by non-affiliates) on the company’s latest cover, with its reference date and SEC link. It does not decide which programs are listed.
- Stage repeats the SEC filing or ClinicalTrials.gov registration wording. Without supporting wording, it is Not stated. Mixed phases retain their exact wording beside the source link.
- Medicine research links use an NCT number stated in the SEC filing or company announcement, or a ClinicalTrials.gov match with sponsor, medicine and phase evidence. A registry match is labelled “matched by ORION (not stated in the filing)”.
- Rows link to the program or company page. For a stated date, month, quarter, half or year, the period ends on its calendar end. Ambiguous qualifiers retain their wording without inferred endpoints.
- Ambiguous periods and events without a date retain the literal wording in a separate section. No calendar date or countdown is created; these records are excluded from calendar subscriptions.
- Active windows have no resolution filing held and end on or after today (UTC). A row with resolution evidence is shown in Results disclosed. Other rows move to Window ended after the stated period ends. Earlier wording and filing links remain available.
- Event types distinguish trial data, enrollment completion, site activation and event-based analysis. Financial results and FDA meetings have their own filters. Audit status remains in the SEC wording. The type follows the SEC wording.
- Displayed items need a true public-display field and a matching SEC quote and timing proof. Machine extraction does not add a founder review.
- “Wording changed” opens the earlier sentences, each with its date and filing.
- No forecast, price, score or signal. The calendar repeats what companies wrote.
Want an email when one of these changes? Get a free Watch.
Window ended
The company-stated period has ended. These records retain their wording and filing links.
1 programs as of
No ended windows match these filters.
Timing without a stated calendar date
These SEC statements retain an ambiguous period or an event trigger. No date or countdown is assigned.
3 records as of
No records match these filters. Choose All periods to view timing without a calendar date.
Results disclosed
An SEC resolution filing is held in these records. The original schedule, quote and source remain available.
47 programs as of
Window ends in: 2025
Grouped by the period end. The company's wording is retained in each row; no countdown is shown.
- RCKTRocket Pharmaceuticals · KRESLADI / RP-L201 · severe leukocyte adhesion deficiency-INDA/BLA submission MatchedSEC ↗Watch
Period the company stated: in 2025
resolve CRL is anticipated in 2025.Details
ROCKET PHARMACEUTICALS, INC. (RCKT) · KRESLADI / RP-L201 · severe leukocyte adhesion deficiency-I
Stage: Not stated
Public float (as of ): $212M (SEC filing) · Under $500M
Period the company stated: in 2025
Submission of a complete BLA to resolve CRL is anticipated in 2025.
Resolution filing (SEC filing)
Earlier SEC statements (6)
- · “submission of complete BLA to resolve Complete Response Letter is anticipated before the end of 2025.” · SEC filing
- · “Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” · SEC filing
- · “Submission of a complete BLA to resolve the CRL is anticipated in 2025.” · SEC filing
- · “Submission of a complete BLA to resolve CRL is anticipated in 2025.” · SEC filing
- · “Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” · SEC filing
- · “Submission of complete BLA to resolve Complete Response Letter anticipated in 2025.” · SEC filing
No disclosed records match these filters.